{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:30:17Z","timestamp":1791293417287,"version":"4.1.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1001\/jamadermatol.2018.0464","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T12:36:32Z","timestamp":1527078992000},"page":"773","source":"Crossref","is-referenced-by-count":92,"title":["Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex"],"prefix":"10.1001","volume":"154","author":[{"given":"Mary Kay","family":"Koenig","sequence":"first","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia S.","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"},{"name":"Department of Dermatology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Roberson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Samuels","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Slopis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"},{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Tate","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Northrup","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the TREATMENT Trial Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"doi180010r1","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16.","volume":"75","author":"European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","journal-title":"Cell"},{"issue":"5327","key":"doi180010r2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.","volume":"277","author":"van Slegtenhorst","year":"1997","journal-title":"Science"},{"issue":"5","key":"doi180010r3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.pediatrneurol.2003.09.002","article-title":"Tuberous sclerosis complex: genetics to pathogenesis.","volume":"29","author":"Narayanan","year":"2003","journal-title":"Pediatr Neurol"},{"issue":"4","key":"doi180010r4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"4","key":"doi180010r5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"6","key":"doi180010r8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jaad.2007.05.021","article-title":"Sirolimus (rapamycin): from the soil of Easter Island to a bright future.","volume":"57","author":"Paghdal","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi180010r9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"doi180010r10","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study.","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"doi180010r11","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1177\/0883073808321764","article-title":"Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex.","volume":"23","author":"Koenig","year":"2008","journal-title":"J Child Neurol"},{"issue":"1","key":"doi180010r12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2045-824X-4-11","article-title":"Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia.","volume":"4","author":"Govindarajan","year":"2012","journal-title":"Vasc Cell"},{"issue":"5","key":"doi180010r13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1067\/mjd.2001.116223","article-title":"Treatment of angiofibromas with a scanning carbon dioxide laser: a clinicopathologic study with long-term follow-up.","volume":"45","author":"Bittencourt","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi180010r14","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bjps.2005.04.021","article-title":"Extensive facial adenoma sebaceum: successful treatment with mechanical dermabrasion: case report.","volume":"58","author":"El-Musa","year":"2005","journal-title":"Br J Plast Surg"},{"issue":"2","key":"doi180010r15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1365-2133.2002.04968.x","article-title":"Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis.","volume":"147","author":"Papadavid","year":"2002","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi180010r16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jdv.2014.29.issue-1","article-title":"Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.","volume":"29","author":"Balestri","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"doi180010r17","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1001\/archdermatol.2011.254","article-title":"Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.","volume":"147","author":"DeKlotz","year":"2011","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi180010r18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/ajd.2012.53.issue-1","article-title":"Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.","volume":"53","author":"Foster","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"7","key":"doi180010r19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","article-title":"Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.","volume":"146","author":"Haemel","year":"2010","journal-title":"Arch Dermatol"},{"key":"doi180010r20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2016.04.003","article-title":"Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex-a comprehensive review of the literature.","volume":"61","author":"J\u00f3zwiak","year":"2016","journal-title":"Pediatr Neurol"},{"issue":"3","key":"doi180010r21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs R D"},{"issue":"4","key":"doi180010r22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/bjd.2011.165.issue-4","article-title":"Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.","volume":"165","author":"Mutizwa","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi180010r23","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1111\/pde.2015.32.issue-3","article-title":"Successful topical rapamycin treatment for facial angiofibromata in two children.","volume":"32","author":"Pynn","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"doi180010r24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/jdv.2012.26.issue-10","article-title":"Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.","volume":"26","author":"Salido","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"doi180010r25","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/bjd.12567","article-title":"First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.","volume":"169","author":"Tanaka","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi180010r26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ajd.2014.55.issue-1","article-title":"Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.","volume":"55","author":"Tu","year":"2014","journal-title":"Australas J Dermatol"},{"issue":"1","key":"doi180010r27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial.","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"7","key":"doi180010r28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/0883073813488664","article-title":"A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.","volume":"28","author":"Wheless","year":"2013","journal-title":"J Child Neurol"},{"issue":"3","key":"doi180010r29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/bjd.2007.156.issue-3","article-title":"The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease.","volume":"156","author":"Basra","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi180010r30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ced.1994.19.issue-3","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"doi180010r31","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.1995.132.issue-6","article-title":"The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use.","volume":"132","author":"Lewis-Jones","year":"1995","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi180010r32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ad.2013.09.013","article-title":"Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.","volume":"105","author":"Kn\u00f6pfel","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"doi180010r33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2017.04.005","article-title":"Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients.","volume":"77","author":"Malissen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi180010r34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/archderm.148.1.138","article-title":"A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.","volume":"148","author":"Wataya-Kaneda","year":"2012","journal-title":"Arch Dermatol"},{"issue":"7","key":"doi180010r35","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamadermatol.2014.4298","article-title":"Clinical and histologic analysis of the efficacy of topical rapamycin therapy against hypomelanotic macules in tuberous sclerosis complex.","volume":"151","author":"Wataya-Kaneda","year":"2015","journal-title":"JAMA Dermatol"},{"key":"doi180010r6","unstructured":"Tuberous Sclerosis Alliance. Tuberous sclerosis complex 2014 constituent survey results. 2015. http:\/\/fliphtml5.com\/tosk\/qyby. Accessed February 14, 2017."},{"key":"doi180010r7","unstructured":"NorthrupH, KoenigMK, PearsonDA, AuKS. Tuberous sclerosis complex. GeneReviews(R), 1999 Jul 13 [Updated 2015 Sep 3]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1220\/. Accessed February 13, 2017."},{"key":"doi180010r36","unstructured":"Drugs@FDA: FDA Approved Drug Products. Prescribing information for Rapamune. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021083s059,021110s076lbl.pdf. Accessed July 9, 2017."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2682034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T18:47:31Z","timestamp":1531334851000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.0464"}},"subtitle":["The TREATMENT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.0464","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,1]]}}}